Shares of Kimberly-Clark Corporation (KMB) fell roughly 3% on Wednesday after the company disclosed significant executive changes tied to its forthcoming acquisition of consumer health products maker Kenvue (KVUE). Kenvue's stock also retreated, declining approximately 2% during the same trading session.

The organizational overhaul arrives as Kimberly-Clark advances toward completing the Kenvue transaction, which is projected to close in the fourth quarter of 2026. It combines an immediate senior departure with a slate of regional leadership appointments for the merged entity, drawn predominantly from Kenvue's current management team. With the changes, several Kenvue regional executives will take charge of the combined company's North America and EMEA (Europe, Middle East and Africa) divisions, while some incumbent Kimberly-Clark leaders step aside. Because these roles determine who runs the combined company's regional businesses and oversees the merger's execution, the restructuring offers an early view of how the merged consumer products company will be managed once the deal closes.

COO Russell Torres to Depart

On September 29, President and Chief Operating Officer Russell Torres informed the organization of his decision to leave. His tenure will conclude on November 2, 2026, as he transitions to assume a chief executive position at another company.

Torres joined Kimberly-Clark in 2020 and also served as head of the Integration Management Office, the body responsible for overseeing the Kenvue transaction. Because he has been directing that integration effort, his exit hands oversight of the pending transaction to other senior leaders.

Integration Duties Redistributed

Two senior executives will assume expanded responsibilities following Torres' departure. Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, will now direct integration planning and execution. Chief Financial Officer Nelson Urdaneta will take charge of synergy realization initiatives, which encompass monitoring the financial benefits and operational improvements anticipated from the merger. The arrangement splits the merger's operational and financial workstreams between two sitting executives rather than concentrating them under a single integration chief.

Kimberly-Clark has also announced the regional leadership structure for the combined company following deal completion.

Regional Leadership Appointments

Carlos De Jesus, presently Kenvue's Group President for North America, will lead the merged company's North America division. John Carmichael, who currently holds that position at Kimberly-Clark, will depart shortly after the transaction completes. De Jesus had previously been designated to become Chief Growth Officer under earlier succession planning and will continue managing the Global Growth Organization throughout the leadership transition.

Leonardo Curado, Kenvue's Group President for Latin America, will move to lead the EMEA division beginning January 1, 2027. He had previously been named the future general manager for Latin America within the combined organization. Carlton Lawson, who currently heads EMEA operations at Kenvue, will conclude his tenure at year-end. Anindya Dasgupta, designated to become President of Enterprise Growth Markets, will assume direct management of Latin America operations.

Stock and Market Context

Analysts maintain an overall Buy rating on KMB shares with a price target of $120, a level that represents a substantial premium to current trading prices following the recent decline. Near-term technical indicators, however, point to a Sell signal despite the favorable long-term analyst sentiment.

Kimberly-Clark typically trades approximately 3.88 million shares daily and maintains a market capitalization of roughly $32.92 billion. The company manufactures tissue products, paper goods, and personal care items, operating in markets where consistent leadership proves critical for ongoing operations.

Kimberly-Clark's portfolio includes widely recognized brands such as Kleenex, Huggies, Scott, Cottonelle, and Kotex, while Kenvue produces consumer health brands including Tylenol, Neutrogena, Listerine, Band-Aid, and Aveeno. Kenvue was spun off from Johnson & Johnson in 2023. Once the transaction closes, the two brand lineups would sit under a single corporate leadership team.

Torres' departure represents the most immediate organizational change affecting investor sentiment. The remaining leadership transitions will not take effect until the Kenvue acquisition reaches completion later this year, with dated checkpoints along the way: Torres' November 2, 2026 exit, Lawson's year-end departure from Kenvue, the deal's projected fourth-quarter close, and Curado's January 1, 2027 move to EMEA.